iMmune SignAtures and Clinical outComes in AP
ConditionAcute Pancreatitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorOhio State University
About this trial
The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of SAP and to identify the specific immune cells that correspond with cytokine signatures in early acute pancreatitis to characterize the immune pathways driving the development of SAP. Participants will provide blood samples and complete patient surveys and interviews within 36 hours of hospital presentation, at 48 hours, and hospital day 7 (if admitted). Data on hospital stay, medical history, clinical course, and severity of disease will be collected.
Eligibility criteria
Qualifiers
Age 18-75 years at the time of enrollment
Diagnosis of acute pancreatitis (AP) according to the revised Atlanta criteria (see definition below)
Participant is approached by the research team within 36 hours of presentation to the hospital
Participant fully understands and agrees to participate in all aspects of the study, including providing informed consent, completion of interviews and data forms, and collection of biospecimens
Disqualifiers
Potential participants with post-ERCP AP who are expected to be hospitalized for less than 48 hours.
Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis.
Confirmed or suspected cystic tumor associated with main pancreatic duct dilation or believed to be the cause of AP (in the site-PI's judgment).
Prior pancreatic surgery, including, but not limited to distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, and Frey procedure.
Trial design
Treatments tested in this trial
- CyTOF Analysis
Treatment groups
198 Participants
are divided into 1 treatment groupSponsors and collaborators
Ohio State University
Lead sponsor
University of Pittsburgh
Collaborator
University of Illinois at Chicago
Collaborator
University of Southern California
Collaborator
Benaroya Research Institute
Collaborator
Source ClinicalTrials.gov